Atle Fund Management AB
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 11, 2026), Atle Fund Management AB reported 39 stock positions worth $309.7 million. Its top holding was Eli Lilly (LLY) at 8.7% of the portfolio, followed by Merck (MRK, 7.4%) and Thermo Fisher Scientific (TMO, 4.7%). Compared with Q4 2025, it opened 4 new positions, sold out of 4, added to 13 and reduced 15. The biggest buy was a new position in Johnson & Johnson (JNJ) and the biggest sale Neurocrine Biosciences (NBIX, shares −5%).
- Most Recent 13F
- Q2 2026
- Location
- STOCKHOLM, V7
- CIK
- 0001381843
- Portfolio Value
- $309.7M (Q1 2026)
- SEC Filing
- 0001381843-26-000004 ↗ filed May 11, 2026
Holdings Value
Holdings 39 stocks · $309.7M
| LLY Eli Lilly & Co. | 8.67% | 39,722 | $26.8M | Add +27.6% |
| MRK Merck & Co. Inc. | 7.40% | 33,853 | $22.9M | Reduce -82.7% |
| TMO Thermo Fisher Scientific Inc. | 4.67% | 22,986 | $14.4M | Reduce -23.2% |
| ONC Beone Medicines Ltd.-ADR | 3.92% | 41,717 | $12.1M | Add +3.2% |
| JNJ Johnson & Johnson | 3.86% | 92,377 | $11.9M | New |
| BBIO Bridgebio Pharma Inc. | 3.84% | 111,363 | $11.9M | Reduce -21.2% |
| VRTX Vertex Pharmaceuticals Inc. | 3.61% | 22,984 | $11.2M | No change |
| ABBV Abbvie Inc. | 3.35% | 108,181 | $10.4M | No change |
| SYK Stryker Corp. | 3.09% | 26,835 | $9.6M | No change |
| ISRG Intuitive Surgical Inc. | 3.05% | 70,851 | $9.4M | Add +217.4% |
| IONS Ionis Pharmaceuticals Inc. | 3.03% | 27,873 | $9.4M | Reduce -69.8% |
| MIRM Mirum Pharmaceuticals Inc. | 3.03% | 195,768 | $9.4M | Add +118.3% |
| CVS CVS Health Corp. | 2.99% | 23,773 | $9.3M | Reduce -77.7% |
| RVMD Revolution Medicines Inc. | 2.93% | 617,245 | $9.1M | Add +584.4% |
| BSX Boston Scientific Corp. | 2.86% | 40,432 | $8.8M | Reduce -62.8% |
| AMGN Amgen Inc. | 2.81% | 21,903 | $8.7M | No change |
| EW Edwards Lifesciences Corp. | 2.67% | 106,518 | $8.3M | New |
| ALKS Alkermes PLC | 2.66% | 242,473 | $8.2M | No change |
| INCY Incyte Corp. | 2.57% | 50,796 | $8.0M | Reduce -28.3% |
| NBIX Neurocrine Biosciences Inc. | 2.54% | 89,685 | $7.9M | Reduce -5.4% |
| GILD Gilead Sciences Inc. | 2.31% | 47,967 | $7.2M | Reduce -5.6% |
| KRYS Krystal Biotech Inc. | 2.19% | 37,579 | $6.8M | Add +11.0% |
| COR Cencora Inc. | 2.13% | 23,470 | $6.6M | Reduce -1.3% |
| IRTC Irhythm Holdings Inc. | 2.02% | 22,322 | $6.3M | Reduce -40.6% |
| INSM Insmed Inc. | 1.92% | 97,438 | $6.0M | Add +249.6% |
| NAMS Newamsterdam Pharma Co. NV | 1.78% | 94,796 | $5.5M | Reduce -51.9% |
| CELC Celcuity Inc. | 1.66% | 141,296 | $5.1M | Add +237.8% |
| ABVX Abivax SA-ADR | 1.54% | 31,590 | $4.8M | No change |
| CAH Cardinal Health Inc. | 1.54% | 108,682 | $4.8M | Add +363.1% |
| IDYA Ideaya Biosciences Inc. | 1.30% | 31,133 | $4.0M | Reduce -68.0% |
| TNGX Tango Therapeutics Inc. | 1.17% | 29,915 | $3.6M | New |
| SYRE Spyre Therapeutics Inc. | 1.13% | 62,735 | $3.5M | New |
| IRON Disc Medicine Inc. | 1.03% | 107,255 | $3.2M | Add +123.6% |
| CMPX Compass Therapeutics Inc. | 0.99% | 41,831 | $3.1M | Reduce -92.8% |
| UNH Unitedhealth Group Inc. | 0.90% | 14,636 | $2.8M | No change |
| DXCM Dexcom Inc. | 0.85% | 584,332 | $2.6M | Add +1371.0% |
| BCAX Bicara Therapeutics Inc. | 0.75% | 1,169,634 | $2.3M | Add +950.3% |
| SLNO Soleno Therapeutics Inc. | 0.71% | 90,184 | $2.2M | Add +43.8% |
| PYXS Pyxis Oncology Inc. | 0.52% | 197,036 | $1.6M | Reduce -68.1% |
Portfolio Sells Q4 2025 → Q1 2026
| NBIX Neurocrine Biosciences Inc. | Reduce -5.4% | 2.54% | −1.75 |
| UFPT Ufp Technologies Inc. | Sold out | 0.00% | −1.63 |
| ACLX Arcellx Inc. | Sold out | 0.00% | −0.87 |
| TMO Thermo Fisher Scientific Inc. | Reduce -23.2% | 4.67% | −0.86 |
| AUTL Autolus Therapeutics PLC | Sold out | 0.00% | −0.74 |
| BSX Boston Scientific Corp. | Reduce -62.8% | 2.86% | −0.45 |
| COR Cencora Inc. | Reduce -1.3% | 2.13% | −0.43 |
| NAMS Newamsterdam Pharma Co. NV | Reduce -51.9% | 1.78% | −0.43 |
| CRBP Corbus Pharmaceuticals Holdi | Sold out | 0.00% | −0.28 |
| IRTC Irhythm Holdings Inc. | Reduce -40.6% | 2.02% | −0.11 |
| CMPX Compass Therapeutics Inc. | Reduce -92.8% | 0.99% | −0.02 |
| IDYA Ideaya Biosciences Inc. | Reduce -68.0% | 1.30% | +0.22 |
| CVS CVS Health Corp. | Reduce -77.7% | 2.99% | +0.30 |
| PYXS Pyxis Oncology Inc. | Reduce -68.1% | 0.52% | +0.30 |
| GILD Gilead Sciences Inc. | Reduce -5.6% | 2.31% | +0.32 |
| INCY Incyte Corp. | Reduce -28.3% | 2.57% | +0.34 |
| BBIO Bridgebio Pharma Inc. | Reduce -21.2% | 3.84% | +0.39 |
| IONS Ionis Pharmaceuticals Inc. | Reduce -69.8% | 3.03% | +0.70 |
| MRK Merck & Co. Inc. | Reduce -82.7% | 7.40% | +0.83 |
Portfolio Buys Q4 2025 → Q1 2026
| JNJ Johnson & Johnson | New | 3.86% | +3.86 |
| EW Edwards Lifesciences Corp. | New | 2.67% | +2.67 |
| TNGX Tango Therapeutics Inc. | New | 1.17% | +1.17 |
| SYRE Spyre Therapeutics Inc. | New | 1.13% | +1.13 |
| MIRM Mirum Pharmaceuticals Inc. | Add +118.3% | 3.03% | +0.77 |
| RVMD Revolution Medicines Inc. | Add +584.4% | 2.93% | +0.64 |
| INSM Insmed Inc. | Add +249.6% | 1.92% | +0.38 |
| CELC Celcuity Inc. | Add +237.8% | 1.66% | +0.33 |
| BCAX Bicara Therapeutics Inc. | Add +950.3% | 0.75% | +0.15 |
| DXCM Dexcom Inc. | Add +1371.0% | 0.85% | +0.01 |
| CAH Cardinal Health Inc. | Add +363.1% | 1.54% | +0.00 |
| ONC Beone Medicines Ltd.-ADR | Add +3.2% | 3.92% | +0.00 |
| IRON Disc Medicine Inc. | Add +123.6% | 1.03% | −0.19 |
| SLNO Soleno Therapeutics Inc. | Add +43.8% | 0.71% | −0.21 |
| KRYS Krystal Biotech Inc. | Add +11.0% | 2.19% | −0.47 |
| ISRG Intuitive Surgical Inc. | Add +217.4% | 3.05% | −0.98 |
| LLY Eli Lilly & Co. | Add +27.6% | 8.67% | −2.01 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 39 | $371.7M | LLY, MRK, JNJ, ABBV, CVS |
| Q1 2026 | 39 | $309.7M | LLY, MRK, TMO, ONC, JNJ |
| Q4 2025 | 39 | $313.4M | LLY, ABBV, MRK, TMO, NBIX |
| Q3 2025 | 38 | $27.0M | LLY, ABBV, NBIX, MRK, TMO |
| Q2 2025 | 37 | $233.7M | LLY, ABBV, BSX, NBIX, MRK |
| Q1 2025 | 37 | $226.5M | LLY, ABBV, UNH, BSX, MRK |
| Q4 2024 | 36 | $210.8M | LLY, UNH, ABBV, BSX, TMO |
| Q3 2024 | 36 | $212.8M | LLY, UNH, MRK, TMO, AMGN |
| Q2 2024 | 38 | $164.0M | LLY, UNH, MRK, TMO, AMGN |
| Q1 2024 | 44 | $164.4M | MRK, LLY, UNH, TMO, NBIX |